A randomised controlled trial of treatment with SSRI or SNRI for patients with functional (psychogenic) dizziness

A randomised controlled trial of treatment with SSRI or SNRI for patients with functional (psychogenic) dizziness - A randomised controlled trial of treatment with SSRI or SNRI for patients with functional (psychogenic) dizziness

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000031958

Enrollment

100

Registered

2018-03-29

Start date

2018-03-29

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

functional (psychogenic) dizziness

Interventions

Treatment based on Selective Serotonin Reuptake Inhibitors(SSRI: escitalopram 10mg) as the main drug for 4 weeks Treatment based on Selective Noradrenaline Reuptake Inhibitors (SNRI: milnacipran 50mg)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with functional (psychogenic) dizziness.

Exclusion criteria

Exclusion criteria: Subjects are excluded if they express suicidal ideation. Other exclusion criteria are currently undergoing treatment with antidepressants or no understanding ability of this study themselves, or no intention of participation

Design outcomes

Primary

Measure	Time frame
Clinical Global Impression improvement(CGI-I) assessed by Psychosomatic physician at 4 weeks	—

Secondary

Measure	Time frame
Symptom of dizziness, the score of Hospital Anxiety and Depression Scale(HADS), Dizziness handicap inventory(DHI) and Visual Symptom Scale-short form(VSS-Sf) at 4 weeks	—

Countries

Japan

Contacts

Public ContactKazuaki Hashimoto

Department of Psychosomatic Medicine, Toho University Graduate School of Medicine Toho University Omori Medical Center

kazuaki.hashimoto@med.toho-u.ac.jp03-3762-4151

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026